Apollomics (NASDAQ:APLM) Raised to “Hold” at Wall Street Zen

Apollomics (NASDAQ:APLM) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Apollomics Price Performance

APLM opened at $24.33 on Friday. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12. The business’s fifty day simple moving average is $19.03 and its 200 day simple moving average is $17.43.

Insiders Place Their Bets

In other news, CEO Hung-Wen Chen bought 270,000 shares of Apollomics stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $13.15 per share, for a total transaction of $3,550,500.00. Following the acquisition, the chief executive officer owned 418,334 shares of the company’s stock, valued at approximately $5,501,092.10. The trade was a 182.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Yi-Kuei Chen purchased 20,000 shares of Apollomics stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $300,000.00. Following the completion of the purchase, the chief operating officer owned 121,248 shares of the company’s stock, valued at $1,818,720. This trade represents a 19.75% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 583,334 shares of company stock worth $8,250,510.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is owned by hedge funds and other institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.